San Diego biotech Singlera Genomics said the FDA has granted Breakthrough Device Designation for its new assay, which detects deadly pancreatic ductal adenocarcinoma in high-risk patients.
San Diego biotech Singlera Genomics said the FDA has granted Breakthrough Device Designation for its new assay, which detects deadly pancreatic ductal adenocarcinoma in high-risk patients.
Sign up for our daily digest of everything you need to know about San Diego — just the essentials, every morning.
By clicking sign up, you agree to the terms.